Physician profile
Janice Keane
NPI 1871502955
$4,699.50
in general payments reported to CMS, 2019-2025
23 companies · $604 in 2025
The $604 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $606 · 2022: $952 · 2023: $1,250 · 2024: $1,287 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,042 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,041.96 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,026.95 | 2021-2025 | |
| Abbvie INC. | $826.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $341.50 | 2021-2025 | |
| Janssen Biotech, INC. | $319.41 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $285.85 | 2022-2025 | Otezla, Otezla |
| Incyte Corporation | $255.62 | 2022-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $251.25 | 2022-2025 | Libtayo, Dupixent |
| Leo Pharma INC. | $225.23 | 2021-2025 | Adbry |
| Dermavant Sciences, INC. | $203.09 | 2023-2024 | Vtama |
| Pfizer INC. | $194.30 | 2022-2025 | |
| Lilly USA, LLC | $117.67 | 2022-2024 | Taltz, Olumiant |
| Ucb, INC. | $95.35 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $94.30 | 2021-2024 | Ilumya, Winlevi |
| Arcutis Biotherapeutics, INC. | $87.64 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $86.65 | 2022-2024 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $82.78 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $67.81 | 2021 | |
| Galderma Laboratories, L.P. | $33.46 | 2024 | |
| Medimetriks Pharmaceuticals, INC. | $25.76 | 2021 | |
| Organon LLC | $24.65 | 2025 | Vtama |
| Epi Health, LLC | $22.65 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.55 | 2021 | |
| Almirall LLC | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Keane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.